Genscript Biotech Co. (OTCMKTS:GNNSF) Short Interest Down 42.3% in June

Genscript Biotech Co. (OTCMKTS:GNNSF) was the target of a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 2,832,000 shares, a decline of 42.3% from the June 15th total of 4,910,000 shares. Based on an average daily trading volume, of 5 shares, the short-interest ratio is currently 566,400.0 days.

Genscript Biotech Price Performance

Shares of GNNSF stock opened at C$1.50 on Friday. Genscript Biotech has a 12-month low of C$1.30 and a 12-month high of C$2.42. The business has a 50 day simple moving average of C$1.62 and a 200 day simple moving average of C$1.62.

Genscript Biotech Company Profile

GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.

The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.